- Home
- / InMed Pharmaceuticals
InMed Pharmaceuticals
Stock Price
$0.3
2024-10-29
Market Capitalization
$3.9 M
2024-10-29
Revenue
$4.9 M
FY, 2025
InMed Pharmaceuticals Summary
Company Summary
- Overview
- InMed Pharmaceuticals is a biopharmaceutical company. It specializes in the discovery and development of cannabinoid-based therapeutics for the treatment of diseases with unmet medical needs.
- Type
- Public
- Status
- Active
- Founded
- 2014
- HQ
- Vancouver, CA | view all locations
- Website
- https://www.inmedpharma.com
- Cybersecurity rating
Table of Contents
Key People
Alexandra D.j. Mancini, Senior Vice President, Clinical & Regulatory Affairs
LocationsView all
2 locations detected
Vancouver, BC HQ
Canada
200 Granville St #340
Vancouver, BC
Canada
W Hastings St
InMed Pharmaceuticals Financials
Summary Financials
- Net income (Q3, 2026)
- ($3.0M)
- Cash (Q3, 2026)
- $5.2M
- EBIT (Q3, 2026)
- ($2.8M)
- Enterprise value
- ($870.1K)